Host Deficiency in Vav2/3 Guanine Nucleotide Exchange Factors Impairs Tumor Growth, Survival, and Angiogenesis In vivo
Vav guanine nucleotide exchange factors modulate changes in cytoskeletal organization through activation of Rho, Rac, and Cdc42 small GTPases. Although Vav1 expression is restricted to the immune system, Vav2 and Vav3 are expressed in several tissues, including highly vascularized organs. Here, we p...
Saved in:
Published in | Molecular cancer research Vol. 7; no. 5; pp. 615 - 623 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Association for Cancer Research
01.05.2009
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Vav guanine nucleotide exchange factors modulate changes in cytoskeletal organization through activation of Rho, Rac, and
Cdc42 small GTPases. Although Vav1 expression is restricted to the immune system, Vav2 and Vav3 are expressed in several tissues,
including highly vascularized organs. Here, we provide the first evidence that Vav2 and Vav3 function within the tumor microenvironment
to promote tumor growth, survival, and neovascularization. Host Vav2/3 deficiency reduced microvascular density, as well as
tumor growth and/or survival, in transplanted B16 melanoma and Lewis lung carcinoma models in vivo . These defects were due in part to Vav2/3 deficiency in endothelial cells. Vav2/3-deficient endothelial cells displayed reduced
migration in response to tumor cells in coculture migration assays, and failed to incorporate into tumor vessels and enhance
tumor volume in tumor-endothelial cotransplantation experiments. These data suggest that Vav2/3 guanine nucleotide exchange
factors play a critical role in host-mediated tumor progression and angiogenesis, particularly in tumor endothelium.(Mol Cancer
Res 2009;7(5):615–23) |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1541-7786 1557-3125 |
DOI: | 10.1158/1541-7786.MCR-08-0401 |